Your browser doesn't support javascript.
loading
Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD.
Feng, Gong; Zheng, Kenneth I; Li, Yang-Yang; Rios, Rafael S; Zhu, Pei-Wu; Pan, Xiao-Yan; Li, Gang; Ma, Hong-Lei; Tang, Liang-Jie; Byrne, Christopher D; Targher, Giovanni; He, Na; Mi, Man; Chen, Yong-Ping; Zheng, Ming-Hua.
Afiliación
  • Feng G; Xi'an Medical University, Xi'an, China.
  • Zheng KI; NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Li YY; Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Rios RS; NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Zhu PW; Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Pan XY; Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Li G; NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Ma HL; NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Tang LJ; NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Byrne CD; Southampton National Institute for Health Research Biomedical Research Centre, Southampton General Hospital, University Hospital Southampton, Southampton, UK.
  • Targher G; Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • He N; Department of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, China.
  • Mi M; Xi'an Medical University, Xi'an, China.
  • Chen YP; NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Zheng MH; Institute of Hepatology, Wenzhou Medical University, Wenzhou, China.
J Hepatobiliary Pancreat Sci ; 28(7): 593-603, 2021 Jul.
Article en En | MEDLINE | ID: mdl-33908180
ABSTRACT

BACKGROUND:

The presence of significant liver fibrosis is a key determinant of long-term prognosis in non-alcoholic fatty liver disease (NAFLD). We aimed to develop a novel machine learning algorithm (MLA) to predict fibrosis severity in NAFLD and compared it with the most widely used non-invasive fibrosis biomarkers.

METHODS:

We used a cohort of 553 adults with biopsy-proven NAFLD, who were randomly divided into a training cohort (n = 278) for the development of both logistic regression model (LRM) and MLA, and a validation cohort (n = 275). Significant fibrosis was defined as fibrosis stage F ≥ 2. MLA and LRM were derived from variables that were selected using a least absolute shrinkage and selection operator (LASSO) logistic regression algorithm.

RESULTS:

In the training cohort, the variables selected by LASSO algorithm were body mass index, pro-collagen type III, collagen type IV, aspartate aminotransferase and albumin-to-globulin ratio. The diagnostic accuracy of MLA showed the highest values of area under the receiver operator characteristic curve (AUROC 0.902, 95% CI 0.869-0.904) for identifying fibrosis F ≥ 2. The LRM AUROC was 0.764, 95% CI 0.710-0.816 and significantly better than the AST-to-Platelet ratio (AUROC 0.684, 95% CI 0.605-0.762), FIB-4 score (AUROC 0.594, 95% CI 0.503-0.685) and NAFLD Fibrosis Score (AUROC 0.557, 95% CI 0.470-0.644). In the validation cohort, MLA also showed the highest AUROC (0.893, 95% CI 0.864-0.901). The diagnostic accuracy of MLA outperformed that of LRM in all subgroups considered.

CONCLUSIONS:

Our newly developed MLA algorithm has excellent diagnostic performance for predicting fibrosis F ≥ 2 in patients with biopsy-confirmed NAFLD.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Hepatobiliary Pancreat Sci Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Hepatobiliary Pancreat Sci Año: 2021 Tipo del documento: Article